" class="no-js "lang="en-US"> Relmada Therapeutics - Medtech Alert
Thursday, March 28, 2024
Relmada Therapeutics | PTF

Relmada Therapeutics

About Relmada Therapeutics

Relmada Therapeutics
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults. In addition, Relmada is advancing a clinical-stage program in neurodegenerative diseases based on psilocybin and select derivative molecules.

Related Story

Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors

January 12 2023

Relmada Therapeutics, a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today […]